Sphera Funds Management LTD. Has $34.59 Million Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Sphera Funds Management LTD. reduced its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 26.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,569,181 shares of the company's stock after selling 561,035 shares during the period. Teva Pharmaceutical Industries accounts for about 6.2% of Sphera Funds Management LTD.'s investment portfolio, making the stock its largest position. Sphera Funds Management LTD. owned about 0.14% of Teva Pharmaceutical Industries worth $34,585,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of TEVA. Oarsman Capital Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth approximately $29,000. Marshall & Sterling Wealth Advisors Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth approximately $44,000. Ameliora Wealth Management Ltd. acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth approximately $66,000. IFP Advisors Inc boosted its position in shares of Teva Pharmaceutical Industries by 96.1% in the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock worth $88,000 after acquiring an additional 1,960 shares during the last quarter. Finally, Quadrant Capital Group LLC boosted its position in shares of Teva Pharmaceutical Industries by 27.7% in the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock worth $96,000 after acquiring an additional 949 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their target price for the stock from $21.00 to $23.00 in a research report on Monday, May 12th. UBS Group decreased their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. Barclays cut their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday, April 23rd. Finally, Bank of America raised their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $24.43.

Teva Pharmaceutical Industries Stock Up 0.5%

Shares of TEVA traded up $0.08 during mid-day trading on Friday, reaching $16.95. 9,758,609 shares of the stock traded hands, compared to its average volume of 10,004,667. The firm has a market cap of $19.22 billion, a price-to-earnings ratio of -11.69, a P/E/G ratio of 1.44 and a beta of 0.62. The stock has a fifty day simple moving average of $15.35 and a 200 day simple moving average of $17.41. Teva Pharmaceutical Industries Limited has a 12-month low of $12.47 and a 12-month high of $22.80. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. The company had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The business's quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.48 earnings per share. Sell-side analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.